AFP and hepatocellular carcinoma: While the diagnostic value of each biomarker in isolation has been the subject of much scientific debate, combining AFP and PIVKA-II has been shown to improve diagnostic efficiency versus each biomarker alone.18 Previously, the serum biomarker-based GALAD model was developed to predict the probability of having HCC in patients with CLD.